Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Recruiting phase 2 trial of de-escalated adjuvant and definitive radiotherapy informed by DART 2.0 circulating tumor HPV DNA, planned enrollment 455. Follow-on to the original DART trial (NCT02908477), in which ctDNA was a secondary correlative rather than the randomization factor.

Mayo Clinic